Photo of Lindsay McNair

Dr. McNair oversees the physician team within the WCG IRBs and provides consultation to institutions and pharma/biotech companies on a wide range of issues related to protocol design, regulatory compliance, human subject protection, and ethical policy development (pre-approval access, subject compensation).

Prior to joining WCG, Dr. McNair was a consultant to multiple biopharma companies, providing medical guidance on clinical development strategies and study designs for new drug studies, as well as medical oversight of all phases of clinical trials. Before becoming a consultant, Dr. McNair was the medical lead for the telaprevir development program at Vertex Pharmaceuticals, with oversight of the phase 1-3 studies.

Dr. McNair is an adjunct faculty member at Boston University, where she teaches graduate courses on the scientific design of clinical research studies.

Dr. McNair earned her medical degree from the University of Connecticut Medical School, a master’s degree in public health from Boston University, and a master’s degree of science in bioethics from Union Graduate College, concentrating in research ethics.

Dr. McNair is an associate editor for the Journal of Empirical Research on Human Research Ethics and serves on multiple committees, including the NYU Compassionate Use Pre-Approval Access (CUPA) Working Group, the Human Subjects Review Board of the US Environmental Protection Agency (EPA HSRB), and the Advancing Effective Research Ethics Oversight (AEREO) consortium.